Article History
Accepted: 26 June 2019
First Online: 1 August 2019
Competing interests
: J.B. has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, Merck, Roche, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea and Nerviano; and has received research and educational grants from Bayer and BTG. L.d.F. has received travel grants from Bayer and speaker fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex and Ipsen. M.R. has received speaker fees from Gilead, BMS, BTG, Lilly and Bayer, and consultancy fees for Bayer, BMS and AstraZeneca.